Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. 1979

W E Evans, and C B Pratt, and R H Taylor, and L F Barker, and W R Crom

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012306 Risk The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome. Relative Risk,Relative Risks,Risk, Relative,Risks,Risks, Relative
D012516 Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed) Sarcoma, Osteogenic,Osteogenic Sarcoma,Osteosarcoma Tumor,Osteogenic Sarcomas,Osteosarcoma Tumors,Osteosarcomas,Sarcomas, Osteogenic,Tumor, Osteosarcoma,Tumors, Osteosarcoma
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

W E Evans, and C B Pratt, and R H Taylor, and L F Barker, and W R Crom
June 1996, Hiroshima journal of medical sciences,
W E Evans, and C B Pratt, and R H Taylor, and L F Barker, and W R Crom
February 1982, La Nouvelle presse medicale,
W E Evans, and C B Pratt, and R H Taylor, and L F Barker, and W R Crom
October 1993, Therapeutic drug monitoring,
W E Evans, and C B Pratt, and R H Taylor, and L F Barker, and W R Crom
August 2002, Therapeutic drug monitoring,
W E Evans, and C B Pratt, and R H Taylor, and L F Barker, and W R Crom
December 2008, Journal of pediatric hematology/oncology,
W E Evans, and C B Pratt, and R H Taylor, and L F Barker, and W R Crom
January 1978, Medicina,
W E Evans, and C B Pratt, and R H Taylor, and L F Barker, and W R Crom
January 1979, Cancer chemotherapy and pharmacology,
W E Evans, and C B Pratt, and R H Taylor, and L F Barker, and W R Crom
January 2005, Acta oncologica (Stockholm, Sweden),
W E Evans, and C B Pratt, and R H Taylor, and L F Barker, and W R Crom
December 2019, Cancer chemotherapy and pharmacology,
W E Evans, and C B Pratt, and R H Taylor, and L F Barker, and W R Crom
October 2009, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
Copied contents to your clipboard!